Oates J C, Ruiz P, Alexander A, Pippen A M, Gilkeson G S
Medical Research Service, Ralph H. Johnson VAMC, Charleston, South Carolina, USA.
Clin Immunol Immunopathol. 1997 Apr;83(1):86-92. doi: 10.1006/clin.1997.4332.
MRL/MpJ-Faslpr (MRL-lpr) and New Zealand Black/ White (NZB/W) mice develop spontaneous autoimmune disease characterized by autoantibody production and glomerulonephritis that progresses in parallel with increasing systemic nitric oxide (NO) production. A previously published study from our laboratory indicated that oral administration of the nitric oxide synthase inhibitor NG-monomethyl-L-arginine (NMMA) before the onset of clinical disease significantly decreased renal and joint pathology in MRL-lpr mice. To characterize the effect of late modulation of NO production in murine SLE, we administered oral NMMA and/or restricted dietary arginine after disease onset in two murine models of SLE. When receiving combined NMMA and arginine restriction, MRL-lpr mice had reduced joint pathology scores and NZB/W mice had lower renal pathology scores than control mice. These results indicate that modulating NO production after the onset of disease diminishes disease severity in two models of SLE, although not as effectively as treating before disease onset.
MRL/MpJ-Faslpr(MRL-lpr)小鼠和新西兰黑/白(NZB/W)小鼠会自发发展出自身免疫性疾病,其特征为自身抗体产生和肾小球肾炎,且该疾病与全身一氧化氮(NO)生成的增加平行进展。我们实验室之前发表的一项研究表明,在临床疾病发作前口服一氧化氮合酶抑制剂NG-单甲基-L-精氨酸(NMMA)可显著降低MRL-lpr小鼠的肾脏和关节病变。为了表征在小鼠系统性红斑狼疮(SLE)中晚期调节NO生成的效果,我们在两种SLE小鼠模型疾病发作后给予口服NMMA和/或限制饮食中的精氨酸。当联合接受NMMA和精氨酸限制时,MRL-lpr小鼠的关节病变评分降低,NZB/W小鼠的肾脏病变评分低于对照小鼠。这些结果表明,在疾病发作后调节NO生成可减轻两种SLE模型中的疾病严重程度,尽管效果不如在疾病发作前治疗那样显著。